European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Psych-STRATA - A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness

Descripción del proyecto

Detección precoz y tratamiento de las resistencias al tratamiento en pacientes psiquiátricos

Los pacientes con trastornos psiquiátricos graves, como la esquizofrenia, el trastorno bipolar y la depresión clínica, suelen desarrollar resistencia al tratamiento farmacológico. Incluso cuando se detectan los primeros signos de resistencia al tratamiento, los pacientes deben someterse a largos procedimientos antes de que los profesionales médicos puedan prescribirles una atención farmacéutica adecuada. El equipo del proyecto Psych-STRATA, financiado con fondos europeos, pretende analizar amplios datos clínicos, genéticos y biológicos de pacientes psiquiátricos para establecer criterios de detección precoz de la resistencia al tratamiento. A partir de sus hallazgos, propondrá estrategias de tratamiento para los pacientes con riesgo de desarrollarla. Además, en el proyecto se crearán modelos de aprendizaje automático capaces de predecir el riesgo de resistencia al tratamiento y la respuesta del paciente al tratamiento, ayudando así a los profesionales sanitarios a ofrecer un tratamiento más personalizado.

Objetivo

A key problem in Mental Health is that up to one third of patients suffering from major mental disorders develop resistance against drug therapy. However, patients showing early signs of treatment resistance (TR) do not receive adequate early intensive pharmacological treatment but instead they undergo a stepwise trial-and-error treatment approach. This situation originates from three major knowledge and translation gaps: i.) we lack effective methods to identify individuals at risk for TR early in the disease process, ii.) we lack effective, personalized treatment strategies grounded in insights into the biological basis of TR, and iii.) we lack efficient processes to translate scientific insights about TR into clinical practice, primary care and treatment guidelines. It is the central goal of PSYCH-STRATA to bridge these gaps and pave the way for a shift towards a treatment decision-making process tailored for the individual at risk for TR. To that end, we aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for TR across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression. PSYCH-STRATA will i.) dissect the biological basis of TR and establish criteria to enable early detection of individuals at risk for TR based on the integrated analysis of an unprecedented collection of genetic, biological, digital mental health, and clinical data. ii.) Moreover, we will determine effective treatment strategies of individuals at risk for TR early in the treatment process, based on pan-European clinical trials in SCZ, BD and MDD. These efforts will enable the establishment of novel multimodal machine learning models to predict TR risk and treatment response. Lastly, iii.) we will enable the translation of these findings into clinical practice by prototyping the integration of personalized treatment decision support and patient-oriented decision-making mental health boards.

Coordinador

UNIVERSITAET MUENSTER
Aportación neta de la UEn
€ 3 804 369,21
Dirección
SCHLOSSPLATZ 2
48149 MUENSTER
Alemania

Ver en el mapa

Región
Nordrhein-Westfalen Münster Münster, Kreisfreie Stadt
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 3 804 369,21

Participantes (23)

Socios (4)